Search

Issue
Title
Authors
No 17 (2013)
Eribulin – novyy mikrotrubochkovyy ingibitor dlya lecheniya metastaticheskogo raka molochnoy zhelezy
Stenina M.B.
PDF
(Rus)
Vol 28, No 7 (2021)
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
Grechukhina K.S., Vorontsova K.A., Kuko T.M., Prosvirnov A.A., Ganshina I.P., Lubennikova E.V., Kolyadina I.V., Zhukova L.G.
PDF
(Rus)
Vol 29, No 11/12 (2022)
The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer
Semiglazov V.F., Krivorotko P.V., Komyakhov A.V., Semiglazova T.Y., Gigolaeva L.P., Tabagua T.T., Kazantseva M.D., Tergoeva A.P., Ulrikh D.G., Chervyak M.V., Klimenko V.V., Amirov N.S., Zhiltsova E.K., Semiglazov V.V.
PDF
(Rus)
No 8 (2015)
Klinicheskiy sluchay uspeshnogo lecheniya erilibulinom metastaticheskogo raka molochnoy zhelezy
Limareva S.V., Laytsan K.Y., Stroyakovskiy D.L., Demidova I.A., Gorbunova V.A.
PDF
(Rus)
Vol 26, No 12 (2019)
Experience of the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative breast cancer
Glazkova E.V., Frolova M.A., Menshikov S.F., Stenina M.B.
PDF
(Rus)
No 8 (2015)
Perspektivy primeneniya kapsul vinorelbina v sovremennoy onkologii
Gutorov S.L., Stepanchenko M.V., Lichinitser M.R.
PDF
(Rus)
No 17 (2017)
Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer
Zhukova L.G., Chichikov E.I., Gordeeva O.O., Filonenko D.A.
PDF
(Rus)
Vol 26, No 7 (2019)
Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis
Vladimirova L.Y., Popova I.L., Abramova N.A., Storozhakova A.E., Tikhanovskaya N.M., Novoselova K.A., Lyanova A.A., Ryadinskaya L.A., Yezhova M.O., Teplyakov M.A.
PDF
(Rus)
No 8 (2013)
NOVYE VOZMOZhNOSTI TERAPII BOL'NYKh METASTATIChESKIM RAKOM MOLOChNOY ZhELEZY, POLUChAVShIKh RANEE ANTRATsIKLINI TAKSAN-SODERZhAShchUYu KhIMIOTERAPIYu: OBZOR LITERATURY I KLINIChESKIY SLUChAY
Zhukova L.G.
PDF
(Rus)
No 18 (2012)
Chemotherapy of anthracy-clineand taxan-resistant breast cancer
Kovalenko E.I., Satirova E.F., Artamonova E.V., Manzyuk L.V.
PDF
(Rus)
No 17 (2016)
RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER"
Artamonova E.V., Bolotina L.V., Gligorov Z., Zhukov N.V., Zhukova L.G., Imyanitov E.N., Karabina E.V., Kovalenko E.I., Lichinitser M.R., Manzyuk L.V., Semiglazov V.F., Semiglazova T.Y., Stroyakovsky D.L.
PDF
(Rus)
Vol 28, No 11 (2021)
Will our clinical practice change with the availability of new diagnostic methods, drug therapy and assessment of its effectiveness? Clinical case: hormone receptor-positive, HER2-negative metastatic breast cancer
Konstantinova M.M., Kuzina L.I.
PDF
(Rus)
No 8 (2015)
KOMPLEKSNAYa TERAPIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Dashyan G.A., Paltuev R.M.
PDF
(Rus)
Vol 28, No 7 (2021)
Olaparib -modern approach to the treatment of BRCA-associated HER2-negative metastatic breast cancer. Clinical experience
Lubennikova E.V., Zhukova L.G., Gordeeva O.O., Drobot N.T., Kuznetsov A.V., Ganshina I.P.
PDF
(Rus)
Vol 26, No 7 (2019)
Oral chemotherapy with vinorelbine for advanced breast cancer: its role in clinical practice
Sakaeva D.D., Nasretdinov A.F.
PDF
(Rus)
No 7 (2018)
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
Sakaev D.D., Iskhakova A.I., Kunafina R.I.
PDF
(Rus)
1 - 16 of 16 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies